Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model

Title
Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model
Authors
Keywords
<sup>161</sup>Tb, <sup>177</sup>Lu, Radioimmunotherapy, Ovarian carcinoma, L1CAM, mAb chCE7
Journal
Publisher
Springer Nature
Online
2014-05-23
DOI
10.1007/s00259-014-2798-3

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now